Valganciclovir

Y. Vivian Tsai, Pharm.D., Kathryn Dzintars, Pharm.D., BCPS

INDICATIONS

FDA

  • Treatment of CMV retinitis (AIDS).
  • Prevention of CMV disease: renal, cardiac, and kidney-pancreas transplant patients at high risk for CMV disease (e.g., donor positive, recipient negative).
    • Not indicated in liver transplant patients.
  • Prevention of CMV disease in renal (4 months to 16 years of age) and cardiac transplant patients (1 month to 16 years of age) at high risk

NON-FDA APPROVED USES

  • Treatment of CMV disease other than HIV-associated retinitis, including mild-moderate CMV disease in SOT when oral therapy is appropriate.
  • CMV prophylaxis after liver/lung transplantation and in selected HCT settings.
  • Treatment of congenital CMV disease.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: November 7, 2026